1. Switzerland Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Lonza Group AG

Lonza Group AG

LZAGY
Lonza Group AGUS flagOther OTC
61.62
USD
-1.35
- -
43.84BMarket Cap
Lonza Group AG
LZAGY
(Other OTC)

Recent

price

61.62

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
4.74
4.83
7.02
6.39
6.49
6.74
7.29
6.7
7.45
5.68
6.06
7.28
8.38
9.12
7.7
9.33
Revenue per Share
0.5
0.28
0.31
0.16
0.42
0.49
0.53
1.04
0.75
0.87
1.17
3.96
1.64
0.89
0.89
-0.39
Basic EPS, GAAP
0.27
-0.08
0.72
0.55
0.54
0.85
0.68
0.57
0.68
0.24
0.21
-0.17
-1.15
-0.4
-0.2
-0.31
Free Cash Flow per Basic Share
0.16
0.2
0.2
0.2
0.2
0.23
0.23
0.24
0.28
0.28
0.28
0.3
0.31
0.36
0.4
0.4
Dividend per Share
3.75
3.48
3.36
3.38
3.38
3.32
3.53
4.24
4
4.91
5.53
9.74
10.95
10.94
11.64
9.94
Book Value per Share
3.06
0.23
0.31
0.49
0.22
0.33
0.08
-2.24
-1.03
-0.21
1.58
5.9
7.51
6.48
5.64
8.11
Tangible Book Value per Share
566
557
559
561
561
564
567
679
744
741
744
743
742
736
712
700
Basic Weighted Avg Shares
2,680
2,692
3,925
3,584
3,640
3,803
4,132
4,548
5,542
4,207
4,508
5,409
6,223
6,717
5,480
6,531
Sales/Revenue/Turnover
13.96
9.7
8.66
7.06
11.62
11.39
12.92
14.31
16.37
20.2
20.67
15.29
21.81
13
16.04
20.79
Operating Margin (%)
273
276
304
309
299
300
307
411
526
544
526
522
596
621
647
813
Depreciation Expense
284
154
174
87
237
277
301
707
559
645
869
2,944
1,215
654
636
-275
Net Income, GAAP
13.94
12
17.14
17.14
15.05
18.77
19.3
- -
18.34
9.87
8.84
10.92
15.88
17.09
14.97
17.44
Effective Tax Rate (%)
10.6
5.72
4.43
2.43
6.51
7.28
7.28
15.55
10.09
15.33
19.28
54.43
19.52
9.74
11.61
-4.21
Profit Margin (%)
336
866
661
655
323
268
433
560
1,134
365
1,704
3,585
2,637
2,139
1,861
3,209
Working Capital
910
2,725
2,427
2,245
1,693
1,414
1,571
3,730
3,621
2,985
2,994
2,530
1,855
2,905
4,608
4,197
LT Debt
2,387
2,137
2,102
2,126
2,130
2,135
2,302
6,181
6,290
6,565
6,884
9,823
10,665
9,512
9,388
7,966
Total Equity
8.24
5.09
5.54
4.32
7.89
8.2
10.27
- -
6.94
7.3
7.96
6.26
8.78
5.55
5.47
8.25
Return on Invested Capital (%)
8.85
4.68
5.7
3.89
7.1
8.63
9.42
- -
8.89
9.75
12.03
33.35
12.14
6.63
6.1
-1.12
Return on Capital (%)
13.53
7.59
9.12
4.61
12.5
14.69
15.53
28.98
19.1
19.5
22.43
51.9
15.82
8.08
7.78
-3.61
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.13%
4.8%
-15.15%
Free Cash Flow
27.8%
68.6%
51.75%
Net Income, GAAP
16.06%
-2.42%
-143.24%
Sales/Revenue/Turnover
6.74%
8.75%
19.18%
Total Cash Common Dividend
- -
6.67%
-2.08%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
6,717
2024
- -
- -
- -
- -
5,480
2025
- -
- -
- -
- -
6,531

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.89
2024
- -
- -
- -
- -
0.89
2025
- -
- -
- -
- -
-0.39

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.36
2024
- -
- -
- -
- -
0.4
2025
- -
- -
- -
- -
0.4
Similar Companies
Justera Health Ltd. (SCRSF)
Vijaya Diagnostic Centre Limited (VIJAYA.BO)
Selvita S.A. (SLV.WA)
Waters Corporation (WAT)
Puriblood Medical Co., Ltd. (6847.TWO)
Spectral Medical Inc. (EDTXF)
Business
Lonza Group AG, a Swiss multinational contract development and manufacturing organization (CDMO), specializes in the production of pharmaceutical, biotechnology, and nutrition ingredients and services for the life sciences industry. Founded in 1897 and headquartered in Basel, Switzerland, the company operates over 30 development and manufacturing sites across Europe, North America, South Asia, and other regions including the United States, United Kingdom, India, China, and Singapore. Lonza provides custom manufacturing of biopharmaceuticals such as monoclonal antibodies, biologics, cell and gene therapies, and biosimilars; small molecule active pharmaceutical ingredients (APIs) including highly potent APIs; bioconjugates and antibody-drug conjugates; drug product services encompassing formulation, fill-finish, vial filling, and lyophilization; detection systems and bioscience tools; as well as capsules, dosage form solutions, and health ingredients for nutraceutical customers. The company serves pharmaceutical, biotech, and nutraceutical firms globally, focusing on end-to-end solutions from drug substance development to commercial-scale manufacturing, with particular strengths in mammalian cell culture, microbial fermentation, and advanced modalities like mRNA and viral vectors. Lonza maintains leadership in CDMO segments including integrated biologics, advanced synthesis, and specialized modalities, reporting strong demand and nearly 20% sales growth in its CDMO business for 2025 alongside a core EBITDA margin approaching 30%. In recent developments, Lonza completed the acquisition of the Genentech biologics manufacturing site in Vacaville, California, from Roche in October 2024 to bolster large-scale mammalian capacity; acquired Synaffix in 2023 to enhance antibody-drug conjugate capabilities; operationalized a new cGMP drug product line in Visp, Switzerland, in 2023 supporting clinical and commercial vial filling; and announced plans in 2024-2025 to divest its Capsules and Health Ingredients division for approximately 2.5 billion euros as part of portfolio optimization and strategic focus on core CDMO operations. Further expansions include a highly potent API facility and large-scale milling in Wyss, Switzerland, ramping up in 2025; bioconjugation site construction in Visp targeting 2027-2028 operations; and ongoing investments like a CHF 500 million drug product facility in Stein, Switzerland, alongside Ibex solutions for complete product lifecycle management at single sites.

Company News

APIChat

  • seekingalpha.com

    Lonza Group AG (LZAGY) Q1 2026 Earnings Call Transcript

  • businesswire.com

    Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products

  • seekingalpha.com

    Lonza: Structural Growth Intact, CHI Exit Strengthens Focus, Recent Weakness Reinforces Entry Opportunity

  • seekingalpha.com

    Lonza Group AG (LZAGY) Discusses Divestment of Capsules and Health Ingredients Business and Focus on CDMO Transformation Transcript

  • businesswire.com

    Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG

  • seekingalpha.com

    Lonza Group Continues To Leverage Biopharma's Optimization Push

  • seekingalpha.com

    Lonza Group AG (LZAGY) Q4 2025 Earnings Call Transcript

  • seekingalpha.com

    Lonza Group AG (LZAGY) Q3 2025 Earnings Call Transcript

  • zacks.com

    PHG vs. LZAGY: Which Stock Is the Better Value Option?

  • zacks.com

    Here's Why Lonza Group (LZAGY) Is a Great 'Buy the Bottom' Stock Now

  • seekingalpha.com

    Lonza Group AG (LZAGY) Q2 2025 Earnings Call Transcript

  • zacks.com

    Lonza Group (LZAGY) Upgraded to Strong Buy: Here's Why

  • seekingalpha.com

    Lonza Group AG (LZAGY) Q1 2025 Earnings Call Transcript

  • zacks.com

    Lonza Group Ag (LZAGY) is a Great Momentum Stock: Should You Buy?

  • zacks.com

    Lonza Group (LZAGY) Upgraded to Buy: Here's What You Should Know

  • seekingalpha.com

    Lonza: Well Equipped In The U.S., Buy Confirmed

  • zacks.com

    NVST or LZAGY: Which Is the Better Value Stock Right Now?

  • zacks.com

    New Strong Sell Stocks for December 23rd

  • zacks.com

    AHCO or LZAGY: Which Is the Better Value Stock Right Now?

  • zacks.com

    AHCO vs. LZAGY: Which Stock Is the Better Value Option?